HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nonprofit Pharmaceutical Companies

465.963

-0.190-0.04%

Number of Gainers:10

Number of Losers:17

Number of Flat:7

PE:- -

High:470.854

Open:466.355

Low:458.442

Close:466.153

Loading ...

FDA: on April 23, Approves Penpulimab-Kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

THOMSON REUTERS

BUZZ-Summit Therapeutics gains as lung cancer drug succeeds in second study in China

Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results

MT Newswires Live

Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%

MT Newswires Live

Ivonescimab in Combination With Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (Sq-Nsclc) VS. Tislelizumab in Combination With Chemotherapy

THOMSON REUTERS

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA

THOMSON REUTERS

BRIEF-JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License

JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others

THOMSON REUTERS

Akeso's NDA for Plaque Psoriasis Drug Gets China Nod

MT Newswires Live

Venus Medtech Reports 2024 Annual Results: Profitability Surges With Robust Global Expansion and Innovations

THOMSON REUTERS

Press Release: Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors

Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients With Ntrk-Positive Solid Tumors

THOMSON REUTERS

Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial

MT Newswires Live

BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23

Akeso - Nmpa Approved Nda of Ebdarokimab, Il-12/Il-23

THOMSON REUTERS

BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis

Akeso: Ebdarokimab Approved in China for Moderate - to - Severe Plaque Psoriasis

THOMSON REUTERS

Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":465.96255,"timestamp":1746000495831,"preClose":466.15277,"halted":0,"volume":90926529,"delay":0,"changeRate":-0.000408,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed Labour Day","change":-0.190216,"latestTime":"04-30 16:00:00","open":466.35526,"high":470.85376,"low":458.44226,"amount":2573153749,"amplitude":0.026625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":3.891859,"peRate":-23.333161,"turnoverRate":0.003412,"increases":10,"decrements":21,"flats":2,"marketCap":269853969728,"floatMarketCap":248722156224},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":470.85376,"amplitude":0.026625,"preClose":466.15277,"low":458.44226,"pbRate":"3.891859","latestPrice":465.96255,"volume":90926529,"delay":0,"open":466.35526,"prevYearClose":331.1933,"prevWeekClose":490.526,"prevMonthClose":465.963,"prevQuarterClose":455.082,"fiveDayClose":475.823,"twentyDayClose":459.856,"sixtyDayClose":321.772,"secType":"PLATE","market":"HK","turnoverRate":0.003412,"peRate":-23.333161,"marketCap":269853969728,"floatMarketCap":248722156224,"timestamp":1746000495831,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":10,"down":17,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530310995","title":"FDA: on April 23, Approves Penpulimab-Kcqx for Non-Keratinizing Nasopharyngeal Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2530310995","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530310995?lang=en_us&edition=fundamental","pubTime":"2025-04-25 04:42","pubTimestamp":1745527344,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250424:nFWN3R237U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516571.SGD","BK1161","BK1574","LU0348784397.USD","LU2488822045.USD","09926","IE00B5MMRT66.SGD","LU1794554557.SGD","LU1720050803.USD","IE00B543WZ88.USD","LU0348783233.USD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2529366502","title":"BUZZ-Summit Therapeutics gains as lung cancer drug succeeds in second study in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2529366502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529366502?lang=en_us&edition=fundamental","pubTime":"2025-04-23 20:05","pubTimestamp":1745409947,"startTime":"0","endTime":"0","summary":"BUZZ-Summit Therapeutics gains as lung cancer drug succeeds in second study in China** Shares of Summit Therapeutics SMMT.O up 13.41% at $31.05 before the bell ** Company and partner Akeso's 9926.HK drug ivonescimab, in combination with chemotherapy, showed \"statistically significant superiority\" in progression-free survival for patients with a type of lung cancer ** The companies were testing ivonescimab-chemotherapy regime in a study conducted in China, against a tislelizumab, and chemotherapy combination ** Tislelizumab is sold as Tevimbra by BeiGene 688235.SS ** The companies plan to share detailed data from the study later this year and SMMT is currently enrolling patients in a multi-regional study for the drug ** SMMT shares peaked in September 2024 after results from a study in China showed some lung cancer patients on its experimental drug had better survival rates than those on Merck's MRK.N blockbuster Keytruda ** BMO analysts say the data \"further heats up competition\" in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nL4N3R1168:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1699723380.USD","LU0208291251.USD","SG9999013999.USD","LU2089984988.USD","LU1585245621.USD","LU2361045086.USD","LU0211331839.USD","LU0266013472.USD","LU0320765489.SGD","IE00BBT3K403.USD","LU0238689110.USD","LU2023250504.SGD","LU1929549753.HKD","LU0265550359.USD","MRK","IE00B2B36J28.USD","IE00B543WZ88.USD","LU2361044949.HKD","LU0203345920.USD","LU1066051225.USD","LU1162221912.USD","LU1989771016.USD","LU1974910355.USD","IE0002141913.USD","SG9999002224.SGD","LU1023059063.AUD","BK4533","BK0239","LU1941712264.USD","LU0289739699.SGD","688235","LU1934455277.USD","IE00BPRC5H50.USD","BK1161","IE00BJT1NW94.SGD","SG9999002232.USD","SG9999014575.USD","LU1794554557.SGD","IE0009355771.USD","LU1571399168.USD","LU2106854487.HKD","LU0965509010.AUD","LU0265550946.USD","SG9999014559.SGD","LU1057294990.SGD","IE00BJJMRZ35.SGD","SMMT","BK1574"],"gpt_icon":1},{"id":"2529522780","title":"Ascletis Pharma's Phase 1B Trial for Obesity Tablets Showed Favorable Safety Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2529522780","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529522780?lang=en_us&edition=fundamental","pubTime":"2025-04-23 17:02","pubTimestamp":1745398942,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said its phase 1B multiple ascending dose study for its ASC30 tablets for obesity showed positive topline results, according to a Wednesday filing with the Hong Kong bourse.The drug showed a favorable safety profile, with gastrointestinal-related adverse events mild and short-lived, the filing said.Trial enrollees did not show serious adverse events, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01672","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"2529448915","title":"Akeso's Lung Cancer Drug Meets Primary Endpoints in China Phase 3 Trial; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529448915","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529448915?lang=en_us&edition=fundamental","pubTime":"2025-04-23 14:44","pubTimestamp":1745390664,"startTime":"0","endTime":"0","summary":"Akeso's  ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.The trial assessed the capabilities of ivonescimab plus chemotherapy against  tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.Shares in the drug company nearly 5% during afternoon trading on Wednesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BPRC5H50.USD","BK1161","IE00B5MMRT66.SGD","LU0348783233.USD","09926","LU2488822045.USD","LU0417516571.SGD","LU1720050803.USD","BK1574","LU1794554557.SGD","IE00B543WZ88.USD","LU0348784397.USD"],"gpt_icon":0},{"id":"2529598069","title":"Ivonescimab in Combination With Chemotherapy Demonstrates Statistically Significant and Strongly Positive Results in First-Line Treatment of Squamous Non-Small Cell Lung Cancer (Sq-Nsclc) VS. Tislelizumab in Combination With Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2529598069","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529598069?lang=en_us&edition=fundamental","pubTime":"2025-04-23 08:16","pubTimestamp":1745367419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250423:nTUA7XFTF3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0417516571.SGD","LU0348783233.USD","LU0348784397.USD","LU1794554557.SGD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","09926","LU1720050803.USD","IE00B543WZ88.USD","BK1574","BK1161"],"gpt_icon":0},{"id":"2529456782","title":"Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral Glp-1R Agonist Asc30 and Submission of 13-Week Phase Iia Study Protocol to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2529456782","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529456782?lang=en_us&edition=fundamental","pubTime":"2025-04-23 07:30","pubTimestamp":1745364602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA702MKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","BK1161","01672"],"gpt_icon":0},{"id":"2529538145","title":"BRIEF-JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License","url":"https://stock-news.laohu8.com/highlight/detail?id=2529538145","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529538145?lang=en_us&edition=fundamental","pubTime":"2025-04-22 23:03","pubTimestamp":1745334225,"startTime":"0","endTime":"0","summary":"BRIEF-JW  Therapeutics Grants Juno Therapeutics Non-Exclusive LicenseApril 22  - JW  Therapeutics Co Ltd 2126.HK:GRANTS JUNO THERAPEUTICS NON-EXCLUSIVE LICENSE UNDER JW SLVV MANUFACTURING PROCESS, OTHERSFurther company coverage: 2126.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02126","BK1161","BK1574","BK1583"],"gpt_icon":0},{"id":"2529587025","title":"JW (Cayman) Therapeutics - Grants Juno Therapeutics Non-Exclusive License Under Jw Slvv Manufacturing Process, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2529587025","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529587025?lang=en_us&edition=fundamental","pubTime":"2025-04-22 22:44","pubTimestamp":1745333076,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nFWN3R00WZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1574","02126"],"gpt_icon":0},{"id":"2529310295","title":"Akeso's NDA for Plaque Psoriasis Drug Gets China Nod","url":"https://stock-news.laohu8.com/highlight/detail?id=2529310295","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529310295?lang=en_us&edition=fundamental","pubTime":"2025-04-22 15:05","pubTimestamp":1745305507,"startTime":"0","endTime":"0","summary":"Akeso's  new drug application  for the ebdarokimab injection recently obtained approval from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.The approval was obtained for the treatment of moderate to severe plaque psoriasis in adult patients, according to the biopharmaceutical company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09926","LU0348783233.USD","IE00B543WZ88.USD","LU2488822045.USD","LU0348784397.USD","IE00B5MMRT66.SGD","BK1574","IE00BPRC5H50.USD","LU0417516571.SGD","BK1161","LU1720050803.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2529004366","title":"Venus Medtech Reports 2024 Annual Results: Profitability Surges With Robust Global Expansion and Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529004366","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529004366?lang=en_us&edition=fundamental","pubTime":"2025-04-22 09:00","pubTimestamp":1745283606,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA1FPKXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02500","BK1574","BK1100"],"gpt_icon":0},{"id":"2529698723","title":"Press Release: Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529698723","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529698723?lang=en_us&edition=fundamental","pubTime":"2025-04-22 09:00","pubTimestamp":1745283600,"startTime":"0","endTime":"0","summary":"Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations. HONG KONG, April 21, 2025 /PRNewswire/ -- Venus MedTech  Inc. , a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 , demonstrating significant improvements in profitability and operational discipline despite market challenges.commercial profit margin rising from 9.35%  to 20.74%.Facing a challenging landscape, Venus Medtech reinforced its leadership in China's valvular therapy sector while achieving significant progress in operational efficiency and commercial profitability, mainly reflected in. -- Sales expenses decreased by 18.44% YoY to RMB245 million, with the sales. expense ratio decreasing from 61.15%  to 52.05% through streamlined. -- R&D expenses declined 35% YoY to RMB341 million, as the Company. prioritized high-value pipeline projects, reducing R&D expense ratio from. entered 63 global markets, with new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1574","02500","BK1583"],"gpt_icon":0},{"id":"2529146870","title":"BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2529146870","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529146870?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:49","pubTimestamp":1745236155,"startTime":"0","endTime":"0","summary":"BRIEF-Zai Lab Announces Acceptance Of Supplemental New Drug Application For Repotrectinib For Patients With NTRK-Positive Solid TumorsApril 21 (Reuters) - Zai Lab Ltd 9688.HK:ZAI LAB ANNOUNCES ACCEPTA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8V4FXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1588","LU2488822045.USD","BK1574","09688"],"gpt_icon":0},{"id":"2529877982","title":"Zai Lab Announces Acceptance of Supplemental New Drug Application for Repotrectinib for Patients With Ntrk-Positive Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2529877982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529877982?lang=en_us&edition=fundamental","pubTime":"2025-04-21 19:30","pubTimestamp":1745235000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8V4FXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09688","BK1588","LU2488822045.USD","BK1161","BK1574"],"gpt_icon":0},{"id":"2529874657","title":"Zhaoke Ophthalmology Enrols First Patient in Dry Eye Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2529874657","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529874657?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:58","pubTimestamp":1745233118,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  has enrolled the first patient in the phase III clinical trial of Cyclosporine  Ophthalmic Gel, an April 17 Hong Kong bourse filing said.The ophthalmic pharmaceutical company is testing the drug for the treatment of moderate to severe dry eye disease.The trial will involve 25 centers and enroll a total of 360 patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1574","BK1587","BK1191","06622"],"gpt_icon":0},{"id":"2529879804","title":"BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23","url":"https://stock-news.laohu8.com/highlight/detail?id=2529879804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529879804?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:27","pubTimestamp":1745231265,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Says NMPA Approved NDA Of Ebdarokimab, Il-12/Il-23April 21 (Reuters) - Akeso 9926.HK:NMPA APPROVED NDA OF EBDAROKIMAB, IL-12/IL-23Further company coverage: 9926.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","LU0417516571.SGD","LU0348783233.USD","09926","LU0348784397.USD","LU1720050803.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","BK1161"],"gpt_icon":0},{"id":"2529769878","title":"Akeso - Nmpa Approved Nda of Ebdarokimab, Il-12/Il-23","url":"https://stock-news.laohu8.com/highlight/detail?id=2529769878","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529769878?lang=en_us&edition=fundamental","pubTime":"2025-04-21 18:15","pubTimestamp":1745230511,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nFWN3QZ064:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0348783233.USD","BK1161","LU1794554557.SGD","LU2488822045.USD","IE00B5MMRT66.SGD","BK1574","IE00B543WZ88.USD","LU0348784397.USD","LU0417516571.SGD","09926","IE00BPRC5H50.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2528067496","title":"BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2528067496","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528067496?lang=en_us&edition=fundamental","pubTime":"2025-04-18 22:18","pubTimestamp":1744985903,"startTime":"0","endTime":"0","summary":"BRIEF-Akeso Ebdarokimab Approved In China For Moderate - To - Severe Plaque PsoriasisApril 18 (Reuters) - Akeso Inc 9926.HK:AKESO: EBDAROKIMAB APPROVED IN CHINA FOR MODERATE - TO - SEVERE PLAQUE PSORI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nFWN3QV3AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU1720050803.USD","LU2488822045.USD","LU0348784397.USD","BK1574","LU0348783233.USD","09926","BK1161","IE00B5MMRT66.SGD","LU0417516571.SGD","LU1794554557.SGD","IE00B543WZ88.USD"],"gpt_icon":0},{"id":"2528063865","title":"Akeso: Ebdarokimab Approved in China for Moderate - to - Severe Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2528063865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528063865?lang=en_us&edition=fundamental","pubTime":"2025-04-18 19:42","pubTimestamp":1744976541,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250418:nFWN3QV3AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1794554557.SGD","IE00BPRC5H50.USD","09926","IE00B5MMRT66.SGD","IE00B543WZ88.USD","BK1161","BK1574","LU0348784397.USD","LU0348783233.USD","LU1720050803.USD","LU0417516571.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2527292479","title":"Zhaoke Ophthalmology, Interpharma Strike Thailand Drug Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2527292479","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527292479?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:16","pubTimestamp":1744802199,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology  entered into three distribution and supply agreements with Interpharma PCL  to commercialize several ophthalmic drugs in Thailand, according to a Wednesday filing with the Hong Kong Exchange.The deals cover NVK002 for myopia progression control, BRIMOCHOL PF for presbyopia, and six generic glaucoma drugs: Bimatoprost, Bimatoprost Timolol, Latanoprost, Latanoprost Timolol, Travoprost, and Travoprost Timolol.Under the agreements, Interpharma gains exclusive rights to import, distribute, market, and sell Zhaoke's products in Thailand and will manage local drug registrations. Zhaoke will then receive non-refundable upfront payments and milestone-based payments.Shares of Interpharma closed nearly 5% higher on Wednesday, while those of Zhaoke slipped 3%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06622","BK1587","BK1191","BK1583","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":39,"code":"91000000","status":"200"}]}}